4.91
4.25%
0.20
Lipocine Inc stock is traded at $4.91, with a volume of 5,715.
It is up +4.25% in the last 24 hours and down -11.69% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$4.71
Open:
$4.71
24h Volume:
5,715
Relative Volume:
0.20
Market Cap:
$25.72M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-2.063
EPS:
-2.38
Net Cash Flow:
$-11.88M
1W Performance:
-5.76%
1M Performance:
-11.69%
6M Performance:
-25.27%
1Y Performance:
+95.62%
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
LPCN | 4.8129 | 25.72M | 0 | -16.35M | -11.88M | -2.38 |
VRTX | 448.16 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 745.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.15 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.82 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
Dec-08-17 | Resumed | H.C. Wainwright | Buy |
Oct-07-16 | Initiated | H.C. Wainwright | Buy |
Jul-22-15 | Initiated | ROTH Capital | Buy |
Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine's LPCN 1148 Shows Breakthrough Results in Liver Disease Clinical Trial | LPCN Stock News - StockTitan
Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
When the Price of (LPCN) Talks, People Listen - Stock Traders Daily
Lipocine: Q3 Earnings Snapshot - CT Insider
Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PR Newswire
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - GuruFocus.com
Lipocine inks deal to bring TLANDO to South Korea - Investing.com
Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com
Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com
Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com
(LPCN) Trading Signals - Stock Traders Daily
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com
Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia
Lipocine reports promising oral brexanolone study results - Investing.com India
Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire
Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance
Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com
Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Citizentribune
Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World
‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily
MediPharm Labs Corp. - Baystreet.ca
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
PLRX’s latest rating updates from top analysts. - Knox Daily
Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World
Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald
Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR
StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World
Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):